Genomics and network formation in the pharmaceutical industry

P. Groenewegen*

*Corresponding author for this work

    Research output: Chapter in Book / Report / Conference proceedingConference contributionAcademicpeer-review


    In the literature various distinctions have been made with regard to the role of networks of R&D alliances. For instance, equity arrangements such as participation, joint ventures and R&D corporations are distinguished from contractual arrangements such as R&D contracts or R&D co-operations. Predominantly however single mode networks have been empirically analyzed based on single criteria such as joint projects or collaborative research agreements. The resulting networks have been discussed and analyzed as important strategic tools to absorb new developments in technology. However, within the literature not much attention is paid the processes in which they are formed, this paper focuses on the latter process. The subject area of attention is the integration of biotechnology, genomics and information technology by new start-ups and their collaborative behavior with existing pharmaceutical and chemical companies. The central question is which differences can be discerned in collaborative patterns.

    Original languageEnglish
    Title of host publicationIEEE International Engineering Management Conference
    Number of pages6
    Publication statusPublished - 2001
    EventChange Management and the New Industrial Revolution (IEMC'01) - Albany, NY, United States
    Duration: 7 Oct 20019 Oct 2001


    ConferenceChange Management and the New Industrial Revolution (IEMC'01)
    Country/TerritoryUnited States
    CityAlbany, NY


    Dive into the research topics of 'Genomics and network formation in the pharmaceutical industry'. Together they form a unique fingerprint.

    Cite this